micafungin (mycamine) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Micafungin (trade name Mycamine) is an echinocandin antifungal drug. Micafungin, the active ingredient in Mycamine, inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls, which is not present in mammalian cells. Micafungin is indicated for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis, abscesses and esophageal candidiasis. Possible histamine-mediated symptoms have been reported with Mycamine, including rash, pruritus, facial swelling and vasodilatation.   NCATS

Chemistry

  • SMILES: CCCCCOc1ccc(cc1)c2onc(c2)c3ccc(cc3)C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)c7ccc(O)c(OS(=O)(=O)O)c7)[C@H](O)CC(=O)N
  • InChIKey: PIEUQSKUWLMALL-YABMTYFHSA-N
  • Mol. Mass: 1270.29
  • ALogP: Missing data
  • ChEMBL Molecules:
    micafungin  
    micafungin sodium  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$26.7100 - $56.3800
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

fk463 | fk 463 | fk-463 | fungard | micafungin | micafungin sodium | micafungin sodium [usan] | mycamine

Organizations (50)

Research & Development (39)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (1)


 

Candidiasis (approved 2005)

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Aspergillosis (Phase 4)

Bone Marrow Transplantation (Phase 1)

Candida (Phase 1)

Candidemia (Phase 4)

Candidiasis (Phase 4)

Candidiasis, Invasive (Phase 4)

Candidiasis, Oral (Phase 3)

Catheter-Related Infections (Phase 1)

Febrile Neutropenia (Phase 2)

Fever (Phase 1)

Fungemia (Phase 3)

Graft vs Host Disease (Phase 2)

Hematologic Diseases (Phase 2)

Hematopoietic Stem Cell Transplantation (Phase 4)

Immunocompromised Host (Phase 1)

Invasive Fungal Infections (Phase 3)

Leukemia, Myeloid, Acute (Phase 4)

Liver Transplantation (Phase 4)

Meningitis (Phase 2)

Mycoses (Phase 4)

Myelodysplastic Syndromes (Phase 4)

Neoplasms (Phase 4)

Neutropenia (Phase 4)

Nutrition Disorders (Phase 4)

Obesity (Phase 4)

Obesity, Morbid (Phase 4)

Overweight (Phase 4)

Sepsis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 58
  • # of Trial Organizations: 39

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue